https://www.selleckchem.com/products/bi-2493.html
Patients with low-risk myelodysplastic syndrome (MDS) and aplastic anaemia (AA) often need transfusions, which may accelerate iron overload. The aim of this study was to evaluate the efficacy, safety and dose-effect relationships of deferasirox (DFX) in patients with low-risk MDS and AA who were refractory to regular treatment in a real-world setting. Patient data were recorded, and dose-effect relationships of DFX were calculated after the first 6months. Total annual exposure to DFX was calculated after 12 months and expressed as the a
Like
Comment
Share
